1	1 TP53 Variant Clusters Stratify the Li-Fraumeni Spectrum and Reveal an					
2	Osteosarcoma-Prone Subgroup					
3						
4	Nicholas W Fischer ¹ , Brianne Laverty ^{1,2} , Noa Alon ¹ , Emilie Montellier ³ , Kara N Maxwell ^{4,5} ,					
5	Christian P Kratz ⁶ , Pierre Hainaut ³ , Ran Kafri ^{7,8} , David Malkin ^{1,2,10,11}					
6						
7	1 Program in Genetics & Genome Biology, The Hospital for Sick Children, Toronto, Canada					
8	2 Department of Medical Biophysics, University of Toronto, Toronto, Canada					
9	3 Institute for Advanced Biosciences, Université Grenoble Alpes, Grenoble, France					
10	4 Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine					
11	the University of Pennsylvania, Philadelphia, PA, USA					
12	5 Department of Genetics, Perelman School of Medicine at the University of Pennsylvania,					
13	Philadelphia, PA, USA					
14	6 Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany					
15	7 Department of Molecular Genetics, University of Toronto, Toronto, Canada					
16	8 Program in Cell Biology, The Hospital for Sick Children, Toronto, Canada					
17	10 Division of Hematology-Oncology, The Hospital for Sick Children, Toronto, Canada					
18	11 Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada					
19 20						
21						
22						
23						
24						
25						
26						
27						
28						
29						

30 ABSTRACT

Li-Fraumeni syndrome (LFS) has recently been redefined as a 'spectrum' cancer predisposition disorder to reflect its broad phenotypic heterogeneity. The wide functional gradient associated with different TP53 variants is thought to contribute to LFS heterogeneity, although it is still poorly understood and there is an unmet clinical need for risk stratification strategies. Leveraging p53 mutagenesis dataset, we performed an unsupervised cluster analysis that revealed five TP53 variant clusters with unique structural and functional consequences. Classifying variant carriers according to these clusters stratified cancer onset and survival using discovery and validation cohorts, and exposed important clinical characteristics to consider for patient management. In particular, we identified a subgroup of monomeric TP53 variant carriers prone to osteosarcoma, along with a cluster associated with less "LFS-like" phenotypes enriched in carriers with no history of cancer. Our classification of TP53 variants demonstrates the existence of a wide TP53-heritable cancer susceptibility spectrum and provides a new framework to delineate carriers toward personalized patient care. Keywords: Li-Fraumeni Syndrome, Spectrum, p53, phenotypic heterogeneity, cancer predisposition, cluster analysis, osteosarcoma

59 **INTRODUCTION**

60 Inherited cancer susceptibility in Li-Fraumeni Syndrome (LFS; MIM #151623) was first described 61 in 1969 based on the observation of several families with a high incidence of rare and diverse 62 cancer types [1]. Since this initial observation, germline TP53 mutations were identified as the 63 underlying cause of LFS [2, 3] and the clinical classification has been adapted by multiple 64 revised sets of criteria [4-7] to incorporate individuals who do not fit the strict 'classic LFS' 65 diagnosis [8]. Recently, LFS was reclassified as a 'spectrum' of disease rather than a syndrome 66 to reflect the heterogeneity that has become increasingly evident through genotype-phenotype 67 association studies [9]. The LFS spectrum encompasses a highly variable age-of-onset with 68 nearly 30% affected during childhood, largely unpredictable sites of tumor manifestation, and 69 inconsistent cancer penetrance. To date, the factors causing this heterogeneity in LFS remain 70 unclear, although unequal mutant p53 functional consequences have been linked to different 71 cancer phenotypes [10-12].

72

73 Increased use of DNA sequencing in the clinic has led to the discovery of hundreds of novel 74 germline variants that span the entire TP53 gene. Missense mutations leading to single amino 75 acid changes represent the vast majority of TP53 variants that are associated with LFS. There 76 are thousands of possible single amino acid substitutions in p53, and currently, at least 1,703 77 different germline variants have been linked to individuals with cancer, as catalogued by the 78 National Cancer Institute's (NCI) TP53 Database (https://tp53.isb-cgc.org). However, research efforts have focused on variants at a few "hotspot" residues that account for only 30% of 79 80 germline TP53 missense variants found in patients, leaving the majority largely uncharacterized 81 and many still considered variants of uncertain significance (VUS). Therefore, it is of great 82 interest to classify all variants in order to provide more accurate cancer risk assessments with 83 tailored surveillance strategies and treatment plans.

84

Mutagenesis studies are an important clinical tool used to assess *TP53* variant pathogenicity,
however, it is often unclear without substantial clinical evidence that is difficult to obtain from
predominantly rare and infrequent variants. The results from large-scale mutagenesis

88 experiments have demonstrated a broad range of functional consequences associated with 89 different variants, ranging from near wild-type (WT) p53 capabilities to severe loss-of-function 90 (LOF) [13-15]. As a multifaceted protein, p53 is composed of several domains containing complex structured and unstructured regions that enable a myriad of cellular tasks. Primarily 91 92 operating as a transcription factor, p53 binds to DNA recognition sequences as a tetramer and 93 regulates the expression of several thousand target genes to orchestrate cellular responses 94 centering around DNA-damage repair (DDR) and cell fate decisions [16]. Hence, mutations 95 arising at different locations of the protein can impart different cellular consequences by 96 altering its transcriptional activity (TA) as well as its non-TA. Some variant p53 species can also 97 exert a dominant-negative (DN) effect over WT p53 [17, 18]. This is an important feature 98 because LFS and heritable TP53-related cancer predisposition follows an autosomal dominant 99 inheritance pattern and most patients are heterozygous carriers who retain one copy of WT 100 TP53. Moreover, mutant p53 LOF can vary under different cellular conditions. For example, the 101 R337H variant—the most frequently reported germline variant due to a genetic founder event 102 in Brazil—has a conditional pH-dependent LOF and is associated with the tissue-specific 103 development of adrenocortical carcinoma (ACC) [19, 20]. Thus, the functional assessments 104 derived from comprehensive variant library screens conducted in varying cellular contexts 105 provide clinically relevant measurements of specific p53 activities.

106

Here, we incorporated p53 variant library screens using an unsupervised cluster analysis and
uncovered five functionally distinct variant clusters. When applied to germline variant carriers
from the NCI *TP53* Database and a validation dataset, we identified unique cancer patterns and
significant differences between ages at onset and cancer survival. Our variant clustering model
provides a new classification tool for variant interpretation and risk stratification of *TP53*variant carriers.

- 113
- 114
- 115
- 116
- 117
- 118

- 119 METHODS
- 120

121 Functional datasets and unsupervised cluster analysis

We selected saturation mutagenesis cellular functional screens as features for dimensionality 122 123 reduction. Giacomelli et al. measured p53 cellular loss-of-function (LOF; nutlin-3 treatment in p53^{NULL} human A549 cells), dominant-negtive activity (DN; nutlin-3 treatment in isogenic p53^{WT} 124 A549 cells), and DNA-damage repair (DDR; etoposide treatment of p53^{NULL} A549 cells) using 125 126 competitive growth assays [14]. Kato et al. measured transcriptional activity (TA) in yeast using 127 a transcriptional reporter assay [13]. We used the median TA values (8 p53 promoter-specific 128 elements) normalized to WT p53. Matrix correlation plots comparing scaled data were 129 generated using *pairplot* in Python's Data Visualization library *Seaborn* using the R package 130 *reticulate*. Dimensionality reduction was performed using PCA (principal component analysis) 131 and UMAP (Uniform Manifold Approximation and Projection) with R packages ggfortify and umap. The R package cluster was used to determine the number of clusters to be generated 132 133 (Gap statistic, elbow method, and silhouette score) and k-means clustering. Data was visualized 134 using the R package *qqplot2*.

135

136 Structure/function analysis

Rendering of the structure of two p53 core DNA-binding domains bound to DNA (PDB #3EXJ)
was done using PyMOL software. Structural/functional domain annotations for each variant
were obtained from the NCI *TP53* Database. Prediction of intrinsically disordered regions was
conducted using IUPred3 [21].

141

142 Clinical datasets, curation, and selection criteria

The National Cancer Institute's (NCI) *TP53* Database (version R20; <u>https://tp53.isb-cgc.org</u>) is a repository for germline variant carriers that was used as the discovery cohort (n=3,446) to evaluate clinical associations. Carriers of multiple variants were removed from the dataset because the relative contribution of the variants is unknown. In addition, carriers of the R337H variant (n=291) were removed from the dataset due to a known sampling bias as a founder

148 variant in Brazil. Patients or tumors with no ID were removed to avoid inclusion of duplicates. 149 The validation dataset (n=458) is a multi-institutional collection of individuals and families 150 carrying germline TP53 variants from registries at three cancer centers: in Canada (The Hospital 151 for Sick Children), the United States (Perelman School of Medicine at the University of 152 Pennsylvania), and Germany (Hannover Medical School). The cohort from Germany included 153 only carriers of pathogenic or likely pathogenic variants based on the Fortuno classification [22]. 154 All carriers of protein-truncating variants (frameshift, non-sense, and deletions) were included 155 as a separate group (FS/NS/DEL) in each analysis.

156

157 **Comparisons with non-cancer associated datasets and the Variant Curation Expert Panel**

158 (VCEP) annotations

- 159 We used the Genome Aggregation Database (gnomAD; <u>https://gnomad.broadinstitute.org/</u>)
- 160 v3.1.2 non-cancer dataset mapped against the canonical transcript (Ensembl transcript ID
- 161 ENST00000269305.9) to investigate the prevalence of variants in the general population with
- 162 no history of cancer. The Fabulous Ladies Over Seventy (FLOSSIES) Database
- 163 (<u>https://whi.color.com/</u>) contains germline DNA sequencing from 27 genes (including *TP53*)
- 164 collected from 10,000 women over 70 years of age who have never had cancer. We identified
- 165 27 *TP53* variants in this dataset and mapped them against the *TP53* clusters. *TP53* variant
- 166 clusters were also compared to VCEP annotations, which were obtained from the ClinVar
- 167 database (<u>https://www.ncbi.nlm.nih.gov/clinvar/</u>).
- 168

169 **Survival analysis**

- The lifetime survival analysis was performed using clinical data obtained from the NCI *TP53* Database and the validation dataset. Unaffected carriers were included as censored events. The 10-year cancer survival analysis was determined using age at diagnosis to age at death. Patients were censored at time of last follow-up if not deceased. The R package *survival* was used to compute Kaplan-Meier (KM) estimates and hazard ratios, and the *survminer* package was used to generate KM plots.
- 176

177 Statistical analy	sis
-----------------------	-----

178 All statistical tests were performed using R or GraphPad Prism (v9). Linear relationships in 179 matrix correlation plots were assessed using Pearson's correlation coefficient. Kruskal-Wallis 180 tests were used to determine differences between functional scores, Grantham's distance, and 181 ages at onset across all groups. Pairwise comparisons were then performed using Mann-Whitney U tests. Chi-squared tests were used to determine significance across groups for 182 cancer type comparisons in variant carriers and differences of proline substitutions in clusters. 183 184 Subsequently, pairwise comparisons were done using Fisher's exact test. All multiple hypothesis 185 corrections for pairwise tests were done using the Benjamini-Hochberg adjustment to obtain 186 the false discovery rate (FDR). KM survival estimates were compared using log-rank tests. 187 Hazard ratios (HR) with 95% confidence intervals (CIs) were calculated using the Cox 188 proportional hazards regression analysis. 189 190 191 RESULTS 192 193 Unsupervised learning identifies five clusters of TP53 variants based on p53 cellular functional 194 features 195 196 Various functional features of p53 have been evaluated using TP53 saturation mutagenesis 197 screens conducted with different cellular systems and drug treatments. These features include 198 TA, DN activity, LOF, DDR, and proliferation [13-15]. Each study has independently reported a 199 wide-ranging functional gradient using separate variant libraries. In a preliminary analysis, we 200 compared the results of these large-scale assays and observed weak to moderately strong inter-201 assay correlations (Fig. 1a and Supplementary Fig. 1a). We found that the correlations were 202 influenced by the variant locations by examining the assay results in relation to the resident 203 functional domains (Fig. 1a and Supplementary Fig. 2a). Strong correlations were observed 204 between variants within the DNA-binding domain (DBD), whereas these relationships were 205 weak or absent for C-terminal domain (CTD) variants. N-terminal domain (NTD) and

oligomerization domain (OD) variants had weak to moderate linear relationships when
comparing between LOF, DDR, and TA, but did not exhibit DN activity, which was almost
exclusively found in DBD variants.

209

210 We employed principal component analysis (PCA) for visualization and dimensionality reduction 211 of the functional features measured by mutagenesis screens covering the p53 protein. At least 212 two spatially separated clusters were visible within a clearly disjointed distribution of data 213 points (Supplementary Fig. 1b). Variants located in the same domain demonstrated a tendency 214 to cluster together, with minimal spatial separation between domains, except for a distinct 215 subgroup of DBD variants (Supplementary Fig. 2b). Notably, each of the cancer-associated 216 hotspot variants as well as monomeric p53 variants were grouped in close proximity, 217 respectively (**Supplementary Fig. 2b**). Next, unsupervised k-means clustering was performed 218 with five predicted clusters (Fig. 1b) as determined by the gap statistical method 219 (Supplementary Fig. 1c). To validate this with a non-linear approach, we applied uniform 220 manifold approximation and projection (UMAP) which demonstrated congruent results to the 221 PCA with a similar spatial distribution of data points with one clearly isolated cluster of DBD 222 variants (Fig. 1c).

223

TP53 variant clusters have distinct signatures affecting different structural and functional characteristics

226

227 By mapping the clusters onto the p53 coding sequence, we identified unique variant signatures 228 (Fig. 1d). First, variants in cluster 1 were found throughout the protein and broadly coincide 229 with intrinsically disordered regions predicted by the IUPred3 computational method [21] (Fig. 230 1d and Supplementary Fig. 3a). In contrast, clusters 2 and 3 were centered within the highly 231 structured DBD. Cluster 3 variants were particularly enriched within helix 2 (H2) of the loop-232 sheet-helix motif (L1/S/H2) that binds to the major groove of DNA, whereas variants in cluster 2 233 were primarily located in regions distal to the DNA contact sites (**Supplementary Fig. 3b, c**). 234 Cluster 4 variants were distinctively concentrated at the CTD (Fig. 1d). Lastly, cluster 5 has a

235 wide variant distribution with three sites of markedly increased variant frequencies located in 236 structured regions known to impact protein stability (Fig. 1d). These three loci were found 237 within TAD1 (transactivation domain 1), OD, and an NTD hinge region (residues 86-93) 238 associated with stabilizing the p53 tetramer through its interaction with the DBD [23]. 239 Specifically, the residues affected most frequently in cluster 5 are involved in binding to the 240 main p53 negative regulator MDM2 (residues F19, W23, and L26) [24], DBD stabilization (W91) 241 [23], p53 oligomerization (I332, R337, and F341), and transactivation (F19, L22, W23, and L26) 242 [25]. We found a significant difference between the expected frequency of proline substitutions, 243 which tend to be more structurally disruptive residues, when comparing between the clusters 244 (p<0.0001, chi-squared test). Cluster 5 contains the most substitutions to/from proline, even 245 after the removal of the proline-rich region (PRR; residues 60-90) (Supplementary Fig. 3d). 246 Clusters 5 and 3 both contain a higher proportion of substitutions to proline compared to 247 clusters 1, 2, and 4 (Supplementary Fig. 3e).

248

249 Substitutions in each cluster were assessed using Grantham's distance, which predicts the 250 evolutionary distance between amino acid substitutions, where higher scores are considered 251 more deleterious. Although cluster 5 contains a higher frequency of proline substitutions, 252 cluster 3 has the highest overall Grantham score compared to all other variant clusters 253 (p<0.0001, Mann-Whitney U test, **Supplementary Fig. 3f**). Collectively, cluster 3 variants have 254 the most severe functional consequences in cellular assays, including a high degree of DN 255 activity (Fig. 2e-h). In contrast, cluster 1 variants are hypermorphic and cluster 4 primarily 256 consists of variants with near-WT functionality. Cluster 2 variants are hypomorphic, exhibiting 257 partial TA, WT-like DDR, and slight DN potential. Lastly, cluster 5 variants exhibit high LOF and 258 impaired DDR, however, most variants in this cluster retain TA and lack DN activity.

259

TP53 variant clusters are clinically relevant and display differing associations with cancer 261

262 The *TP53* Variant Curation Expert Panel (VCEP) plays an important role in evaluating molecular

and clinical evidence to provide variant interpretations accessible through ClinVar

264 (https://clinicalgenome.org/affiliation/50013) [26]. VCEP uses variant functional information, 265 including the mutagenesis assays used in our variant clustering model, in addition to clinical and 266 population data to determine variant pathogenicity. However, TP53 variants can be exceedingly 267 rare and often lack sufficient clinical evidence to establish a clear association with cancer-268 particularly those with reduced penetrance or adult onset [27]. Thus, despite great efforts, only 269 109 of 2,314 potential missense variants within the gene have undergone evaluation, and still, 270 24 of these remain VUS. We compared the 109 VCEP annotated variants to our unsupervised 271 clustering model to examine the clinical relevance of each variant cluster (Fig. 2a). A 272 remarkable division was observed between pathogenic/likely pathogenic (P/LP) and 273 benign/likely benign (B/LB), with cluster 3 displaying a complete separation for P/LP and cluster 274 1 for B/LB. Using our strategy, variant interpretations of P/LP and B/LB could be extended to 275 over 1100 variants classified in clusters 1 and 3. Within clusters 2, 4, and 5, the distribution of 276 VCEP annotated variants were mixed or contained more VUS. If TP53 variant pathogenicity is a 277 gradient resulting in a spectrum of cancer risk, then clusters 2, 4, and 5 may represent 278 intermediate pathogenicity between B/LB cluster 1 and P/LP cluster 3. Subsequently, we 279 explored germline sequencing datasets to determine the prevalence of each variant cluster in 280 individuals with or without a history of cancer (Supplementary Table 1). Cancer-associated germline variants in the NCI TP53 Database were predominantly classified in cluster 3 281 282 (1998/3,113 or 64%) (Fig. 2b). Similarly, cluster 3 variants also comprised over 64% of those 283 identified in a multi-institutional validation dataset (n=458) collected from cancer centers 284 across Canada, the United States, and Germany (Fig. 2c). Non-cancer associated germline 285 variants from the gnomAD database, representing the general healthy population, were most 286 often classified in cluster 1 (79/186 or 42.5%) (Fig. 2d). Moreover, cluster 1 variants were highly 287 enriched in healthy older women >70 years (19/27 or 70%) with no history of cancer (FLOSSIES 288 database) (Fig. 2e). Overall, the divergence of variant clusters in germline carriers affected 289 versus unaffected by cancer and the alignment with VCEP annotations supports the potential 290 value of our clustering strategy to delineate germline carriers into risk stratified groups. 291

292 Classification of TP53 variant carriers based on clusters reveals unique cancer-type 293 distributions and an osteosarcoma-prone subgroup

294

295 Individuals carrying a pathogenic germline TP53 variant are affected by a broad range of 296 cancers during childhood and adulthood. We classified TP53 variant carriers in the NCI TP53 297 Database based on the five clusters and investigated the cancer-type distributions in each 298 group. Carriers of protein-truncating variants (frameshift, nonsense, and deletions; FS/NS/DEL) 299 were included as another variant group. Each group of patients exhibited a diverse range of 300 cancers (Fig. 3a), however, our analysis revealed significant differences (chi-squared test) 301 between the occurrence of specific cancer types when comparing across all groups 302 (Supplementary Table 2). Strikingly, osteosarcomas occurred at more than twice the frequency 303 in patients carrying a cluster 5 variant (15.8%; 16/101 patients) compared to all other cluster-304 based groups (p<0.0001, chi-squared test) (Fig. 3b and Supplementary Table 3). Pairwise 305 comparisons determined that the odds of developing osteosarcoma for cluster 5 variant 306 carriers is significantly higher than in all other cluster-based patient groups, with odds ratios of 307 (OR)=6.3 versus cluster 1 (95% confidence interval (CI)=2.1-22.8; FDR=0.0015, Fisher's exact 308 test), OR=4.6 versus cluster 2 (95% CI=2.0-10.6; FDR=0.0015, Fisher's exact test), OR=2.5 versus 309 cluster 3 (95% CI=1.3-4.4; FDR=0.0092, Fisher's exact test), and OR=14.5 versus cluster 4 (95% 310 Cl=2.2-622; FDR=0.0029, Fisher's exact test) (Supplementary Table 4). This association did not 311 reach significance when comparing cluster 5 to FS/NS/DEL carriers in which the frequency of 312 osteosarcoma was 9.0% (71/788 patients) (OR=1.9; 95% CI=0.98-3.5; FDR=0.065, Fisher's exact 313 test). All bone tumors in cluster 5 (n=17) were classified as osteosarcomas with the exception of 314 one unclassified bone sarcoma (not otherwise specified). Notably, upon analysis of the TP53 315 variants in cluster 5 patients, we found that the majority were located in the OD and known to 316 abolish oligomerization, resulting in monomeric p53 species (L344P, R337C, R337L, R337P, and 317 R342P, in 81 of 88 individuals from 20 unrelated families) [12, 28]. For carriers of a monomeric 318 p53 variant, osteosarcomas represented 16.8% (16/95 patients) of all cancers developed in this 319 subgroup (Supplementary Table 3).

320

321 Next, we observed a greater proportion of colorectal cancers in cluster 1 variant carriers. 322 Colorectal cancer is considered relatively uncommon in LFS, representing 3.4% (136/3987) of 323 total cancers in NCI TP53 Database. However, we found a significant difference between the 324 patient groups (p=0.0007, chi-squared test), in which cluster 1 carriers exhibited the highest 325 frequency of colorectal cancer affecting 9.2% (16/174) of patients (Fig. 3c and Supplementary 326 Table 5). In addition, we identified a significant difference between the expected frequencies of 327 the core cancers that are commonly associated with LFS: osteosarcoma, soft tissue sarcomas 328 (STS), breast tumors, brain tumors, adrenocortical carcinoma (ACC), and leukemia (p<0.0001, 329 chi-squared test) (Supplementary Table 6). Interestingly, carriers of cluster 1 variants presented 330 with considerably fewer LFS core cancers (49.7%) versus all other patient groups which each 331 totalled approximately 70% LFS core cancers (Fig. 3d). The odds of manifesting an LFS core 332 tumor for cluster 1 carriers was at least 2.1-fold lower than all other groups (FDR<0.015, 333 Fisher's exact test) (Supplementary Table 4). Together, these observations of unique tumor 334 patterns suggest that TP53 variant structural and functional features can impact cancer 335 pathogenesis in germline carriers.

336

337 **TP53** variant clusters significantly stratify cancer onset and survival of carriers

338

339 Carriers of TP53 variants endure a lifelong high susceptibility to cancer with wide-ranging ages 340 at onset, and some experience multiple cancers. After separating TP53 variant carriers into 341 cluster-based groups, we found significant differences between the ages at diagnosis of cancer 342 (p<0.0001, Kruskal-Wallis test) (Fig. 4a,b). Cancer diagnoses were significantly earlier in carriers 343 of clusters 3, 5, and FS/NS/DEL variants when compared to carriers of variants in clusters 1, 2, 344 and 4, with median age differences of at least 7 years (Fig. 4a and Supplementary Table 7). 345 Importantly, our validation cohort demonstrated the same pattern of divergent ages at 346 diagnosis (p<0.0001, Kruskal-Wallis test), where cluster 1 carriers exhibited the oldest onset, 347 while clusters 3, 5, and FS/NS/DEL carriers consistently displayed the earliest onset (Fig. 4b and 348 Supplementary Table 7).

350 Upon analysis of cancer diagnoses in the NCI TP53 Database, we noticed a drastic increase in 351 frequency for cluster 5 carriers around age 30 due to a surge of breast tumor cases (Fig. 4a). 352 Breast tumor onset varied considerably between the groups (p<0.0001, Kruskal-Wallis test), 353 and again, carriers of clusters 3, 5, and FS/NS/DEL variants each had significantly earlier onset 354 when compared to carriers of variants in clusters 1, 2, and 4 (Fig. 4c and Supplementary Table 355 7). Furthermore, in our analysis of ACC diagnosis, which is typically within the first few years of life, we found a significant difference between the patient groups (p=0.0095; Kruskal-Wallis 356 357 test). In this case, cluster 4 variant carriers manifested ACC during young adulthood with a 358 median age at diagnosis of 23 years, whereas all other patient groups experienced early childhood-onset ACC (Fig. 4c and Supplementary Table 7). 359

360

361 Finally, we investigated whether the TP53 variant clusters could stratify the cancer survival of 362 carriers. The Kaplan-Meier plot in Figure 5a shows that the lifetime cancer survival between 363 cluster-based patient groups was significantly different (p<0.0001, log-rank test). Recapitulating 364 the pattern of cancer onset, carriers of variants in clusters 1, 2, and 4 had considerably 365 prolonged survival (median ages 74, 68, and 68, respectively) when compared to clusters 3, 5, 366 and FS/NS/DEL carriers (median ages 52, 47, and 54, respectively) (Supplementary Table 8). 367 The validation cohort demonstrated a similar trend in lifetime cancer survival (p=0.039, log-368 rank test) (Fig. 5b). Of note, the differences in observed survival time for cluster 5 when 369 comparing the NCI TP53 Database and validation dataset is likely due to monomeric p53 370 carriers. The validation cohort had only 1 monomeric variant carrier of 5 total cluster 5 carriers 371 with survival data, whereas cluster 5 in the NCI TP53 Database was comprised entirely of 372 monomeric variant carriers (n=45). In addition, the observed shift in lifetime cancer survival 373 between the NCI and validation datasets can be attributed to differences in data collection. The 374 NCI TP53 Database is a historical repository containing multigenerational data which provides 375 lifelong survival projections. The validation dataset contains current patient records, some of 376 which are pediatric, with less multigenerational data. As such, the validation cohort has more 377 unaffected carriers with less lifetime data as compared to the NCI TP53 Database

378 (Supplementary Table 9), thus contributing to the discrepancy since the risk of death increases379 over time.

380

381 In order to obtain adequate sample sizes with complete clinical data to analyze 10-year survival 382 time after cancer diagnosis, we clustered patients into 2 groups (cluster 1.2 and 2.2) rather than 383 5 and kept FS/NS/DEL as an additional patient group (Supplementary Fig. 4). In this model, 384 cluster 1.2 variants displayed greater structural and functional consequences as compared to 385 cluster 2.2 variants (Supplementary Figure 4d-g). Remarkably, the cancer survival between 386 these two patient groups along with FS/NS/DEL carriers was significantly different using data 387 from the NCI TP53 Database (p=0.0027, log-rank test) (Fig. 5c). Intriguingly, we observed an 388 even greater stratification between survival outcomes when using the validation cohort 389 (p=0.0068, log-rank test). In both cases, cluster 2.2 variant carriers had significantly extended 390 cancer survival compared to cluster 1.2 (Supplementary Table 10). The differences in 10-year survival outcomes when using the NCI versus the validation cohort can be explained by the 391 392 differences in cancer types between the datasets. Specifically, the validation cohort contained 393 more breast tumors and fewer bone tumors when compared to the NCI TP53 Database 394 (Supplementary Table 11). Overall, this data suggests that the functionally distinct TP53 variant 395 clusters can stratify the cancer onset and survival of germline carriers, representing a promising 396 risk stratification strategy for patients where there is currently none.

397

398 **DISCUSSION**

399

The broad phenotypic spectrum related to *TP53* variants necessitates a risk stratification
strategy. Diagnosis of LFS and the understanding of specific cancer risk is still a challenge
because *TP53* variants are often rare with limited clinical evidence to base decisions on. The
population prevalence of pathogenic variants is also unclear for the same reasons. Strikingly, *TP53* variants leading to protein changes occur in 7.8% of the general population (based on
gnomAD v4.0, n=807,162 individuals; not including WT variant P72R), however most are likely
benign. Current estimates suggest that pathogenic variants are found in 1 in 3555-5476

individuals [29]. This number was suggested to be as high as 1 in 400-865 using a less stringent
definition of pathogenicity, although it is now considered an overestimate. Clarity around
variant interpretations will help to avoid misclassification and improve patient management.

411 Here, we integrated functional screens using dimensionality reduction to gain a better 412 understanding of the impact of different p53 variant species on their diverse cellular activities, 413 including TA, DDR, LOF, and DN activity. Previous models to predict variant pathogenicity 414 treated it as a binary variable and limited the focus to pathogenic versus benign [30, 31]. These 415 studies did not examine the clinical effects of variants, whereas our approach has refined the 416 categorization of pathogenicity and related these findings to clinical features to explore the 417 spectrum of genetic variants. Using unsupervised clustering we identified 5 distinct TP53 418 variant clusters with unique functional properties and clinical relevance. **Table 1** summarizes 419 the main structural/functional features and clinical outcomes in each variant cluster, and 420 Supplementary Table 12 provides a reference for variant cluster assignments. Comparison of 421 expert annotated variants with the clusters revealed a B/LB (cluster 1) and a P/LP (cluster 3) 422 group, as well as three other groups with mixed pathogenicity interpretations or largely VUS 423 (Fig. 2a). Since the majority of variants are not classified by VCEP and remain VUS, we used the 424 clustering approach to classify all variants and found unique associations to cancer. Cluster 3 425 contained the most variants linked to cancer, and cluster 1 variants were the most prevalent in 426 a non-cancer dataset (Fig. 2b-e). Moreover, cluster 1 variants were enriched in women >70 427 years who never had cancer.

428

We then tested the clinical impact by grouping carriers according to the clusters using discovery and validation cancer-associated datasets. Clear distinctions between groups, including unexpected findings, and consistent patterns emerged throughout our study. Specifically, a significantly higher frequency of osteosarcoma was discovered among cluster 5 carriers of monomeric p53 variants (Fig. 3b). Cluster 1 variant carriers presented with fewer LFS core cancers and a greater proportion being colorectal tumors (Fig. 3c,d). Furthermore, cancers in cluster 1 carriers were largely adult-onset and the lifetime survival in this group of patients was

considerably extended compared to clusters 3, 5, and FS/NS/DEL groups (Fig 4a,b and Fig. 5a,b).
In contrast, cluster 3 variants, which were primarily DBD variants with DN activity, predisposed
to earlier cancer onset with shorter lifetime survival (Fig. 4 and Fig. 5a,b). Cluster 2 variants
were also mostly DBD variants but without DN activity, comprising a group of variants with
intermediate pathogenicity compared to clusters 3 and 1. Cluster 4 carriers also displayed
intermediate pathogenicity, and were distinguished by the delayed onset of ACC in young
adulthood (Fig. 4d).

443

444 Taken together, the enrichment of cluster 1 variants in populations with no cancer history and 445 the milder phenotypes associated with these carriers (i.e. older onset, superior lifetime survival, 446 and less LFS-like tumor profiles) suggests that cluster 1 variants are B/LB. Their presence in the 447 NCI TP53 germline dataset may be a result of sampling bias. In fact, the relatively higher 448 proportion of colorectal cancer in this variant cluster compared to other clusters reflects the 449 proportion of worldwide cancer diagnoses that are colorectal cancer (10%) according to the 450 World Health Organization. Previous work has suggested that multigene panel testing in 451 colorectal cancer has expanded the mutational analysis of TP53 to a wider range of patients, 452 including those who do not meet classic LFS criteria, which can result in sampling bias that 453 inflates cancer risk estimates [32].

454

455 A limitation of this study was the smaller sample size of the validation cohort that restricted the 456 cancer type-specific analyses. Within the validation dataset, patient selection in the German 457 cohort was more stringent for the inclusion of P/LP variants according to the Fortuno criteria 458 [22], thus restricting the representation of variants in clusters outside of these criteria. In 459 addition, the limited availability of clinical information made the analysis of survival after 460 diagnosis less statistically rigorous when using 5 groups. However, by implementing a 2-cluster 461 model to investigate 10-year survival, we found a remarkable separation between outcomes 462 (Fig. 5c,d). In this model, cluster 1.2 variants encompassed the most severe functional 463 consequences (including DN and monomeric variants) and led to significantly reduced survival 464 time after diagnosis of cancer (Supplementary Figure 4h and Supplementary Table 10).

465

466 The current results suggest that a cancer risk continuum related to TP53 variants extends 467 beyond the LFS spectrum and can be risk stratified using integrative metrics (Fig. 6). At one end 468 of the risk continuum, we find that cluster 1 variants retain higher functionality and are 469 tolerable B/LB variants that were likely ascertained in association with cancer due to sampling 470 bias (Fig. 2d,e). In contrast, we also identified high-risk variant carriers of clusters 3, 5, and FS/NS/DEL variants that result in earlier onset and poorer overall survival. The observation of 471 472 reduced penetrance in clusters 2 and 4 may be the result of conditional variant pathogenicity 473 under the influence of genetic or environmental modifying factors. Overall, the variant clusters 474 provide a comprehensive new classification for variant interpretations and reveal novel risk factors that can be used to tailor an individual's tumor surveillance plan and set clinical 475 476 expectations. Considerations for modifying surveillance protocols according to the TP53 variant 477 clusters include (1) greater attention to bone lesions in whole-body MRI images from 478 monomeric variant carriers; (2) intensive screening (particularly very early-onset breast cancer) 479 for clusters 3, 5, and FS/NS/DEL carriers; (3) less intensive screening for clusters 2 and 4 carriers; 480 (4) no screening recommended for cluster 1 carriers. Future development of this approach by 481 incorporating more innovative mutagenesis screens may lead to even more refined risk 482 stratification and personalized medicine. 483

484 **ACKNOWLEDGEMENTS**

This work is supported in part by a Terry Fox New Frontiers Program Project grant from the
Terry Fox Research Institute (#1084). D.M. holds the CIBC Children's Foundation Chair in Child
Health Research. C.P.K. has been supported by the BMBF ADDRess (01GM2205A) and by
the Deutsche Kinderkrebsstiftung (DKS2021.25).

489

490 **REFERENCES**

 Li, F.P. and J.F. Fraumeni, Jr., *Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome*. J Natl Cancer Inst, 1969. **43**(6): p. 1365-73.
 Malkin, D., et al., *Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms*. Science, 1990. **250**(4985): p. 1233-8.

495 3. Srivastava, S., et al., Germ-line transmission of a mutated p53 gene in a cancer-prone 496 family with Li-Fraumeni syndrome. Nature, 1990. 348(6303): p. 747-9. 497 4. Birch, J.M., et al., Prevalence and diversity of constitutional mutations in the p53 gene 498 among 21 Li-Fraumeni families. Cancer Res, 1994. 54(5): p. 1298-304. 499 Eeles, R.A., Germline mutations in the TP53 gene. Cancer Surv. 1995. 25: p. 101-24. 5. 500 Chompret, A., et al., Sensitivity and predictive value of criteria for p53 germline mutation 6. 501 screening. J Med Genet, 2001. 38(1): p. 43-7. 502 Tinat, J., et al., 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin 7. 503 Oncol, 2009. 27(26): p. e108-9; author reply e110. 504 Li, F.P., et al., A cancer family syndrome in twenty-four kindreds. Cancer Res, 1988. 8. 505 48(18): p. 5358-62. 506 Kratz, C.P., et al., Analysis of the Li-Fraumeni Spectrum Based on an International 9. 507 Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis. JAMA Oncol, 2021. 7(12): p. 1800-1805. 508 509 Kennedy, M.C. and S.W. Lowe, Mutant p53: it's not all one and the same. Cell Death 10. 510 Differ, 2022. 29(5): p. 983-987. 511 Sabapathy, K. and D.P. Lane, Therapeutic targeting of p53: all mutants are equal, but 11. 512 some mutants are more equal than others. Nat Rev Clin Oncol, 2018. **15**(1): p. 13-30. 513 Fischer, N.W., et al., Association Between the Oligomeric Status of p53 and Clinical 12. 514 Outcomes in Li-Fraumeni Syndrome. J Natl Cancer Inst, 2018. 110(12): p. 1418-1421. 515 Kato, S., et al., Understanding the function-structure and function-mutation relationships 13. 516 of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc 517 Natl Acad Sci U S A, 2003. 100(14): p. 8424-9. 518 Giacomelli, A.O., et al., Mutational processes shape the landscape of TP53 mutations in 14. 519 human cancer. Nat Genet, 2018. 50(10): p. 1381-1387. 520 Kotler, E., et al., A Systematic p53 Mutation Library Links Differential Functional Impact 15. 521 to Cancer Mutation Pattern and Evolutionary Conservation. Mol Cell, 2018. **71**(5): p. 873. 522 16. Fischer, M., Census and evaluation of p53 target genes. Oncogene, 2017. 36(28): p. 523 3943-3956. 524 Willis, A., et al., Mutant p53 exerts a dominant negative effect by preventing wild-type 17. 525 p53 from binding to the promoter of its target genes. Oncogene, 2004. 23(13): p. 2330-8. 526 Gencel-Augusto, J. and G. Lozano, *p53 tetramerization: at the center of the dominant-*18. 527 negative effect of mutant p53. Genes Dev, 2020. 34(17-18): p. 1128-1146. 528 Pinto, E.M., et al., Founder effect for the highly prevalent R337H mutation of tumor 19. suppressor p53 in Brazilian patients with adrenocortical tumors. Arg Bras Endocrinol 529 530 Metabol, 2004. 48(5): p. 647-50. 531 DiGiammarino, E.L., et al., A novel mechanism of tumorigenesis involving pH-dependent 20. 532 destabilization of a mutant p53 tetramer. Nat Struct Biol, 2002. 9(1): p. 12-6. 533 Erdos, G., M. Pajkos, and Z. Dosztanyi, IUPred3: prediction of protein disorder enhanced 21. 534 with unambiguous experimental annotation and visualization of evolutionary 535 conservation. Nucleic Acids Res, 2021. 49(W1): p. W297-W303. 536 22. Fortuno, C., et al., An updated quantitative model to classify missense variants in the 537 TP53 gene: A novel multifactorial strategy. Hum Mutat, 2021. 42(10): p. 1351-1361.

538	23.	Natan, E., et al., Interaction of the p53 DNA-binding domain with its n-terminal extension
539		modulates the stability of the p53 tetramer. J Mol Biol, 2011. 409 (3): p. 358-68.
540	24.	Kussie, P.H., et al., Structure of the MDM2 oncoprotein bound to the p53 tumor
541		suppressor transactivation domain. Science, 1996. 274(5289): p. 948-53.
542	25.	Raj, N. and L.D. Attardi, The Transactivation Domains of the p53 Protein. Cold Spring
543		Harb Perspect Med, 2017. 7(1).
544	26.	Fortuno, C., et al., Specifications of the ACMG/AMP variant interpretation guidelines for
545		<i>germline TP53 variants</i> . Hum Mutat, 2021. 42 (3): p. 223-236.
546	27.	Fischer, N.W., Y.V. Ma, and J. Gariepy, Emerging insights into ethnic-specific TP53
547		germline variants. J Natl Cancer Inst, 2023. 115 (10): p. 1145-1156.
548	28.	Kawaguchi, T., et al., The relationship among p53 oligomer formation, structure and
549		transcriptional activity using a comprehensive missense mutation library. Oncogene,
550		2005. 24 (46): p. 6976-81.
551	29.	de Andrade, K.C., et al., Higher-than-expected population prevalence of potentially
552		pathogenic germline TP53 variants in individuals unselected for cancer history. Hum
553		Mutat, 2017. 38 (12): p. 1723-1730.
554	30.	Carbonnier, V., et al., Comprehensive assessment of TP53 loss of function using multiple
555		<i>combinatorial mutagenesis libraries</i> . Sci Rep, 2020. 10 (1): p. 20368.
556	31.	Ben-Cohen, G., et al., TP53_PROF: a machine learning model to predict impact of
557		<i>missense mutations in TP53</i> . Brief Bioinform, 2022. 23 (2).
558	32.	Terradas, M., et al., TP53, a gene for colorectal cancer predisposition in the absence of
559		Li-Fraumeni-associated phenotypes. Gut, 2021. 70 (6): p. 1139-1146.
560		



Figure 1. Unsupervised cluster analysis of *TP53* missense variants based on cellular p53 functional features. **(a)** Matrix correlation plots comparing functional datasets from p53 mutagenesis datasets covering the entire protein (LOF = loss-of-function; DDR = DNA damage repair; DN = dominant negative activity; TA = transcriptional activity). Variants are colour-coded based on the functional domain they reside in (NTD = N-terminal domain; PRR = proline-rich region; DBD = DNA-binding domain; OD = oligomerization domain; CTD = C-terminal domain). **(b)** Principal component analysis (PCA) and unsupervised k-means clustering performed with p53 mutagenesis cellular functional assay measurements. **(c)** Uniform manifold approximation and projection (UMAP) performed using p53 mutagenesis cellular functional assay measurements and colour-coded based on PCA k-means clustering (N=200, D=0.4). **(d)** Heatmap displaying the codon frequencies and distributions of *TP53* variant clusters. Red arrowheads indicate mutational hotspots in cluster 5. **(e-h)** Violin plots displaying the functional consequences of variants within each cluster (dotted line represents wild-type p53). P-values on plots were calculated using Kruskal-Wallis tests. Mann-Whitney U tests were used for pairwise comparisons (****p<0.0001).



Figure 2. Alignment of *TP53* clusters with the Variant Curation Expert Panel (VCEP) annotations and the representation of clusters across populations with and without cancer. **(a)** Stacked bar plot showing VCEP annotated variants (n=109) applied to the variant clusters. **(b)** Bar charts displaying the frequencies of germline variants in each cluster found in the NCI *TP53* Database (n=3,113), **(c)** a multi-institutional validation cohort (n=458), **(d)** gnomAD non-cancer dataset (n=186), and (e) FLOSSIES database (n=27). P-values on plots were calculated using chi-square tests.



Figure 3. Cancer spectrums in germline *TP53* variant carriers classified based on the variant clusters. **(a)** Stacked bar plot displaying the cancer type distribution patterns manifested in germline *TP53* mutation carriers. **(b)** Bar charts showing the frequency of osteosarcoma, **(c)** colorectal cancer, **(d)** and LFS-core cancer types according to the cluster-based patient classification. Pvalues on plots were calculated using chi-square tests. Fisher's exact tests were used for pairwise comparisons (*p<0.05, **p<0.01, ***p<0.001).



Figure 4. Age at cancer diagnosis in germline *TP53* variant carriers. **(a)** Line plot displaying the cumulative cancer diagnosis ages over time and a box and whiskers plot (10-90th percentiles) representing the ages at cancer diagnosis in the NCI *TP53* Database, and **(b)** in the validation cohort. *compared to clusters 1, 2, and 4. **(c)** Line plot displaying the frequency of breast tumor diagnosis over time and a box and whiskers plot (10-90th percentiles) representing the ages at cancer diagnosis. *compared to clusters 1, 2, and 4. **(d)** Line plot displaying the frequency of ACC diagnosis over time and box and whiskers plot (10-90th percentiles) representing the age at ACC onset. *compared to clusters 2, 3, and FS/NS/DEL. P-values on plots were calculated using Kruskal-Wallis tests. Mann-Whitney U tests were used for pairwise comparisons (*p<0.05, **p<0.01, ***p<0.001).



Figure 5. Survival analysis of *TP53* variant carriers. (a) Kaplan-Meier plots displaying the lifetime cancer survival of *TP53* variant carriers from the NCI *TP53* Database and (b) a validation cohort, stratified based on the variant clusters. (c) Kaplan-Meier plots showing 10-year survival time (age at cancer diagnosis to age at death) of *TP53* variant carriers from the NCI *TP53* Database and (d) a validation cohort, based on the 2-cluster model. p-values were calculated using the log-rank test.



LOW RISK

PATHOGENICITY

HIGH RISK



Figure 6. Interpretation of *TP53* variant clusters as a cancer susceptibility continuum based on cellular functional and clinical evidence.

Variant Group	Structural Features and Regions	Functional Features	Defining Cancer Phenotypes	Cancer onset (median age in years with 95% CI)	Lifetime cancer survival (median age in years with 95% Cl)
Cluster 1	Disordered regions	Hypermorphic	Late onset/Less LFS core cancers	42 (37-46)	74 (69-NA)
Cluster 2	DBD non-contact sites	Hypomorphic	-	39 (35-41)	68 (63-80)
Cluster 3	DBD contact sites	LOF/DN	Very early onset breast cancer	29 (28-30)	52 (49-54)
Cluster 4	СТD	WT-like function	Young adult ACC onset	37 (31-47)	68 (63-NA)
Cluster 5	OD (monomeric) /TAD1/NTD hinge region	LOF/Hypomorphic	Osteosarcoma/Very early onset breast cancer*	30 (28-33)	47 (33-NA)*
FS/NS/DEL	Protein truncating	LOF	Very early onset breast cancer	28 (27-30)	54 (47-NA)

Table 1. Summary of structural/functional features and clinical phenotypes associated with *TP53* variant clusters.

 *Data from monomeric variant carriers